Navigation Links
VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD
Date:7/1/2009

Patients took the PERMP test one half hour before their first dosing and then at 2, 4, 8, 10, 12, and 14 hours after dosing at two visits (visits 5 and 6) during the double-blind crossover phase.

VYVANSE demonstrated significant improvement in the average total PERMP scores, 312.9 for the VYVANSE group compared to 289.5 for the placebo group; P< .0001. Also, at each postdose assessment from two hours to 14 hours, the VYVANSE group had significantly better average PERMP total scores than the placebo group, (P< .01 for all). At the first time point measured, two hours postdose, the average change from predose measurement in total PERMP scores for the VYVANSE group was 41.5 versus 22.5 for the placebo group; P< .001.

In addition to PERMP, the investigators measured the efficacy of VYVANSE using the ADHD-RS with adult prompts, which is a standardized test for assessing symptoms of ADHD and for assessing response to treatment. This scale, which contains 18 items, is based on the ADHD diagnostic criteria as defined in the APA's Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, a publication of the American Psychiatric Association. In this study, VYVANSE demonstrated a reduction (approximately 52 percent) from baseline in average ADHD-RS total scores in adults, from 37.2 at baseline to 18.1 at visits 5 and 6. Adult patients taking placebo also demonstrated a reduction (approximately 21 percent) in average ADHD-RS total scores, from 37.2 at baseline to 29.6 at visits 5 and 6.

The study also assessed the safety of VYVANSE, finding that the most frequently reported adverse events (greater than or equal to 5 percent) for patients during the dose-optimization phase were decreased appetite, dry mouth, headache, insomnia, upper respiratory tract infection, irritability, nausea, anxiety, and feeling jittery.

VYVANSE, which was introduced in the United States in July 2007 for the treatment of ADHD
'/>"/>

Contact: Matthew Cabrey (Shire North America)
484-595-8248
Porter Novelli
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
2. VYVANSE provided behavior, inattention and math test score improvements in children with ADHD
3. Phase III pivotal results presented of VYVANSE to treat ADHD in adults
4. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
5. FDA approves additional dosage strengths of Vyvanse
6. Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track
7. VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment
8. Record Number of Volunteers Provided Free Dental Care to Needy Children in Minnesota
9. Chronic Pain Patients Now Have Hope With Carryover Pain Relief Provided By Repeated Interferential Treatments
10. National Institutes of Health Expands Use of Emergency Notification Services Provided by Send Word Now(TM) Across NIH Campus
11. $5.15 Million Provided to Support Local Health Care Needs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... As the Muscular Dystrophy Association continues to enhance ... hired two new Scientific Program Officers, Amanda Haidet-Phillips, Ph.D ... Grace Pavlath, Ph.D, who joined MDA late last year ... together will lead MDA as it accelerates new front-line ... types of neuromuscular and motor neuron diseases. ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Parents need ... fatal reality of substance use disorders. School programs like ... be marginally successful. NOPE, or Narcotics Overdose Prevention and ... according to Healthline News on Feb. 27th. ... and prescription opiate drugs, drug prevention proponents are lobbying ...
(Date:3/6/2015)... Anaheim, Cailfornia (PRWEB) March 06, 2015 ... lifestyle technology company, announced today the launch of ... save money on healthy and sustainable products at ... retailers. Makeena is exhibiting at Expo West Booth ... to search by gluten-free, Kosher, non-GMO, organic, Paleo, ...
(Date:3/6/2015)... TN (PRWEB) March 06, 2015 Since ... January 1, 2015, there has been an overwhelming demand ... an efficient and compliant CCM program. The Centers ... on several matters. , PYA’s updated white paper—“ ... this new guidance into a detailed, yet practical “how ...
(Date:3/6/2015)... 2015 Jvion, the Atlanta-based leader ... a Clostridium Difficile (C Diff) predictive use case ... use case is the latest in a broad ... infections, chronic conditions, and individual illnesses. Using the ... solution flags at risk individuals to help support ...
Breaking Medicine News(10 mins):Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:A Harbor Village Detox Clinical Psychologist Encourages School Programs like NOPE to Positively Impact Awareness of Substance Use Disorders 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Updated PYA White Paper Meets Demand for Guidance on Providing and Billing Medicare for Chronic Care Management 2Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... new study challenges the widespread perception that bulimia primarily ... Blair Waldorf, who battled bulimia on the show earlier ... American are 50 percent more likely than girls who ... girls from families in the lowest income bracket studied ...
... Start of a Long-Term Trend in Infant HealthWHITE PLAINS, N.Y., ... in 2007 - a finding that the March of Dimes ... trend in improved maternal and infant health. The preterm birth ... preterm) and among babies born to African American and white ...
... Solutions and Patient Questionnaires for Clinical Trials announced that it has ... to collect data from patients at home on electronic diaries in ... ... AZ (PRWEB) March 18, 2009 -- assisTek, the Leader in ...
... 18 Nuvilex, Inc. (OTC Bulletin Board: NVLX), formerly ... , the world,s first permanent tattoo ink designed to be ... alt.news 26.46 television segment shown on February 22, 2009 on ... and development of the ink as well as its use ...
... Suggests Parents Most Influence Teens, Decisions About SexWASHINGTON, March 18 ... 1% in 2007, according to data released today by the ... second year in a row that the teen birth rate ... decline in the teen birth rate. That is, after ...
... that the PSA test is a far from perfect tool ... offer conflicting views on the value of screening men with ... , But at least one leading oncologist says this much ... family history of prostate cancer should pay attention to a ...
Cached Medicine News:Health News:Black girls are 50 percent more likely to be bulimic than white girls 2Health News:Black girls are 50 percent more likely to be bulimic than white girls 3Health News:Preterm Birth Rate Drops 2Health News:Preterm Birth Rate Drops 3Health News:Preterm Birth Rate Drops 4Health News:Smart Phones to be used by assisTek to Collect Patient-Reported Outcomes in a Large Multinational Clinical Trial 2Health News:Smart Phones to be used by assisTek to Collect Patient-Reported Outcomes in a Large Multinational Clinical Trial 3Health News:Nuvilex' Infinitink Tattoo Ink Featured on PBS alt.news 26:46 TV Program 2Health News:Teen Birth Rate Up For Second Year in a Row 2Health News:2 Studies Conflict Over Value of Prostate Cancer Screening 2Health News:2 Studies Conflict Over Value of Prostate Cancer Screening 3
(Date:3/6/2015)... 2015  AbbVie (NYSE: ABBV ) will ... Thursday, March 12, 2015. Richard A. Gonzalez , ... question and answer session at 8:30 a.m. Central time. ... will be accessible through AbbVie,s Investor Relations Web site ... session will be available later that day. ...
(Date:3/6/2015)... March 6, 2015 Troyen A. Brennan, M.D., ... CVS Health (NYSE: CVS ), will speak ... Washington, D.C. today.  Brennan will outline ... addressing health care cost and quality as the overall ... the first national pharmacy chain to stop selling tobacco ...
(Date:3/6/2015)... , March 6, 2015   Veracyte, Inc. ... demonstrating that diagnostic tests that use increasing numbers of ... reduce the specificity of test results, leading to an ... erroneously diagnosed as cancerous. In addition, these new data ... the malignancies leading to "false negatives." The data were ...
Breaking Medicine Technology:CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 2CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 3Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 2Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 3Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 4Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 5Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 6
For the quantitative determination of direct & total bilirubin in serum. Modified Malloy-Evelyn Diazotization Method. Endpoint Reaction Product measured at 540 nm. Linearity: 20 mg/dl...
... Spectrophotometers are simple, reliable ... use in many types ... clinical, industrial and environmental ... vial holders, Windows based ...
Spectra 5000 is one of the most versatile analytical devices used in conventional laboratories which can work in the ultravoilet and visible range from 200 to 1000 nm for quantitative and qualitative...
... 400 Series Spectrophotometer ... approach to UV-VIS instrumentation. ... are incorporated into a ... in features and performance ...
Medicine Products: